AIxCrypto Holdings (AIXC) Q4 2024 earnings summary

Executive summary

• Early-clinical-stage therapeutics company focused on cancer, with lead program QN-302 in Phase 1a and preclinical Pan-RAS program.

• Significant restructuring in 2023, including sale of diagnostics business and reduction in force.

• Entered co-development agreement with Marizyme for DuraGraft, providing funding in exchange for future royalties.

• Implemented expense controls and slowed R&D due to financial constraints.

Financial highlights

• Net loss from continuing operations was $6.2 million for 2024, improved from $13.8 million in 2023.

• General and administrative expenses decreased to $4.2 million (from $6.1 million), and R&D expenses dropped to $1.2 million (from $5.2 million) year-over-year.

• $360,000 credit loss expense recognized on Marizyme notes receivable.

• Cash and cash equivalents at year-end 2024 were $1.2 million; accumulated deficit reached $123.1 million.

• Raised $8.0 million in new equity and $3.5 million in new debt during 2024.

Outlook and guidance

• Cash expected to fund operations only into Q3 2025; additional financing required to continue as a going concern.

• Management plans to ramp up development of therapeutics pipeline when properly funded.

• Substantial doubt remains about ability to continue as a going concern without new capital.